A monthly prescription for prostate-cancer drug Zytiga costs about $118 on Cuban’s website, compared with $4,195 through Cigna, $2,056 through CVS and $205 through UnitedHealth.
A nonprofit launched its own generic version of Zytiga last year.
CivicaScript, a nonprofit founded by hospitals, the Blue Cross Blue Shield Association and other insurers to reduce drug costs, launched its own generic version of Zytiga last year for the equivalent of about $142 per prescription.
Yet it found very few specialty pharmacies willing to carry it, said Allan Coukell, senior vice president for public policy at Civica Rx, the parent of CivicaScript.
Part of the problem is that Zytiga is sold through specialty pharmacies, the majority of which are owned by PBMs, Coukell wrote in a March letter to the Senate Finance Committee, which is investigating PBMs.
“The same entity that is theoretically working on behalf of health plans, consumers, and Medicare to reduce drug costs also has an incentive to maximize its revenues from dispensing,” Coukell wrote.